GILD reports positive results for Livdelzi in PBC patients with mild ALP elevation
Tweet Send to a Friend
Gilead Sciences Inc. (NASDAQ: GILD) announced that its Phase 3 IDEAL trial of Livdelzi (seladelpar) met its primary endpoint in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
